<?xml version="1.0" encoding="UTF-8"?>
<ref id="B20-vaccines-07-00074">
 <label>20.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Moore</surname>
    <given-names>P.L.</given-names>
   </name>
   <name>
    <surname>Ranchobe</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Lambson</surname>
    <given-names>B.E.</given-names>
   </name>
   <name>
    <surname>Gray</surname>
    <given-names>E.S.</given-names>
   </name>
   <name>
    <surname>Cave</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Abrahams</surname>
    <given-names>M.-R.</given-names>
   </name>
   <name>
    <surname>Bandawe</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Mlisana</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Abdool Karim</surname>
    <given-names>S.S.</given-names>
   </name>
   <name>
    <surname>Williamson</surname>
    <given-names>C.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection</article-title>
  <source>PLoS Pathog.</source>
  <year>2009</year>
  <volume>5</volume>
  <elocation-id>e1000598</elocation-id>
  <pub-id pub-id-type="doi">10.1371/journal.ppat.1000598</pub-id>
  <pub-id pub-id-type="pmid">19763271</pub-id>
 </element-citation>
</ref>
